Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion

Xiaoyuan Lin, Weiwei Xue, Yueping Zhang, Beibei Fu, Jakob Trimpert, Na Xing, Dušan Kunec, Wanyan Tang, Yang Xiao, Kaiwen Meng, Shuobo Shi, Haibo Wu, Geng Meng, Zhenglin ZhubioRxiv 2021 · DOI

TL;DR

This study reveals that mutations in the SARS-CoV-2 nucleocapsid (N) protein, specifically at position 203, synergize with spike (S) protein mutations like L452R to enhance viral fitness, immune evasion, and transmission. These findings highlight the critical, often overlooked, role of N protein mutations in the evolution and dominance of SARS-CoV-2 variants, including Delta.

What Problem Does This Paper Address?

The rapid evolution of SARS-CoV-2 into various Variants of Concern (VOCs) has been a major challenge for public health. While much research has focused on mutations in the spike (S) protein, which is the primary target for vaccines and antibodies, the role of mutations in other viral proteins, particularly the nucleocapsid (N) protein, has been less understood. This paper addresses the question of how mutations in the N protein, specifically at position 203 (R203M in the Delta variant), contribute to the increased transmissibility, infectivity, and immune evasion observed in dominant SARS-CoV-2 variants. The authors aim to elucidate the synergistic effects of N protein mutations with known S protein mutations, like L452R, in driving viral evolution and the emergence of successful variants.

Methods

The researchers employed a multi-pronged approach:

  • Epidemiological Analysis: They analyzed a large dataset of SARS-CoV-2 genomic sequences to track the prevalence and evolutionary trends of specific mutations, particularly R203M and L452R, across different geographical regions and time periods. Statistical methods like Mann-Kendall trend tests and Fisher's exact tests were used to assess significance.
  • Viral Replication Assays: They constructed SARS-CoV-2 variants with specific mutations (L452R, R203M, and combinations) using reverse genetics. These mutant viruses were then used to infect cell lines (Vero E6, Calu-3) and primary human airway tissue models to assess viral replication efficiency and infectivity.
  • In Vivo Studies: Hamsters were infected with wild-type and mutant viruses to evaluate viral replication in different tissues (nasal wash, trachea, lungs) and assess pathological outcomes.
  • Neutralization Assays: Sera from infected hamsters were used to test the neutralization capacity against different viral variants, assessing the degree of immune evasion conferred by specific mutations.
  • Fitness Analysis: The relative fitness of variants was evaluated by analyzing their prevalence changes over time in relation to vaccination coverage, using population genetics principles.
  • Structural Analysis: Preliminary investigations into the polymerization state of the N protein were conducted using size exclusion chromatography to explore potential mechanistic links between N protein mutations and viral fitness.

Datasets

The study utilized a large dataset of 3,438,667 full-length SARS-CoV-2 genomic sequences collected from December 2019 to September 2021. These sequences were sourced from public databases including GISAID, NCBI, and CoVdb. Additionally, clinical information from 115,032 SARS-CoV-2 strains was gathered from GISAID for functional prediction based on patient outcomes.

Key Insights and Ideas

  • Synergy is Key: The most striking insight is the synergistic effect between N protein mutations (like R203M) and S protein mutations (like L452R). This combination significantly amplifies viral fitness and immune evasion beyond what either mutation confers alone.
  • N Protein's Underappreciated Role: The study strongly suggests that N protein mutations are not mere passengers but active drivers of SARS-CoV-2 evolution, playing a crucial role in the rise and dominance of successful variants.
  • Vaccination as a Selective Pressure: The increased fitness of the R203M/L452R variant, particularly after the initiation of global vaccination programs, points to vaccination as a significant selective pressure that favors variants with enhanced immune evasion capabilities.
  • Mechanism of Evasion: While the precise mechanism is still under investigation, the study hints that changes in the polymerization state of the N protein might be involved in the synergistic effect, potentially influencing viral assembly and immune evasion.

Key Results

  • Enhanced Fitness: The R203M/L452R variant exhibited a statistically significant higher growth rate and transmission fitness compared to the L452R-only variant across global, continental, and country-level analyses.
  • Reduced Neutralization: The combination of R203M and L452R mutations led to a substantial decrease (3.2-fold on average) in the neutralization titers of sera from infected hamsters, indicating significant immune evasion.
  • Increased Infectivity and Replication: In cell culture and hamster models, the R203M/L452R and R203K/L452R variants showed increased viral replication and infectivity compared to the L452R-only variant.
  • Correlation with Vaccination: The relative fitness of the R203M/L452R variant showed a continuous increase that was significantly correlated with vaccination coverage, suggesting a role for vaccination in driving the selection of this variant.
  • N Protein Polymerization: Preliminary structural analysis indicated that the R203M mutation may alter the polymerization state of the N protein, potentially contributing to its synergistic effect with S protein mutations.

Limitations and Future Work

  • Mechanistic Understanding: The authors acknowledge that the detailed biochemical and structural mechanisms by which N protein mutations, particularly R203M, exert their effects remain unclear. They emphasize the need for more extensive biochemical and structural research to characterize the biological function of these mutations.
  • Virulence Not Significantly Increased: While the study demonstrated increased infectivity and immune evasion, it did not observe a significant increase in disease severity (virulence) associated with the R203M/L452R variant compared to the L452R-only variant in hamsters. However, they suggest that this does not rule out a contribution to disease severity and calls for more comprehensive surveys.
  • Omicron and Future Variants: The presence of the 203 mutation in the Omicron variant suggests a potentially universal effect, highlighting the need for continued monitoring and attention to this mutation in emerging SARS-CoV-2 variants. Future work should focus on elucidating the precise molecular mechanisms underlying the observed synergistic effects and immune evasion.

Summary updated

Abstract

Abstract Previous work indicated that the nucleocapsid 203 mutation increase the virulence and transmission of the SARS-CoV-2 Alpha variant. However, Delta later outcompeted Alpha and other lineages, promoting a new wave of infections. Delta also possesses a nucleocapsid 203 mutation, R203M. Large-scale epidemiological analyses suggest a synergistic effect of the 203 mutation and the spike L452R mutation, associated with Delta expansion. Viral competition experiments demonstrate the synergistic effect in fitness and infectivity. More importantly, we found that the combination of R203M and L452R brings in a 3.2-fold decrease in neutralizing titers to the neutralizing serum relative to L452R-only virus. R203M/L452R show an increased fitness after the initiation of global vaccination programmes, possibly associated with the enhanced immune evasion. Another rapidly emerging variant Omicron also bears the 203 mutation. Thus, we proposed that nucleocapsid mutations play an essential role for the rise and predominance of variants in concern.
BibTeX
@misc{lin2021nucleocapsid,
  author = {Xiaoyuan Lin and Weiwei Xue and Yueping Zhang and Beibei Fu and Jakob Trimpert and Na Xing and Dušan Kunec and Wanyan Tang and Yang Xiao and Kaiwen Meng and Shuobo Shi and Haibo Wu and Geng Meng and Zhenglin Zhu},
  title = {{Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion}},
  year = {2021},
  doi = {10.1101/2021.12.20.473471},
  howpublished = {bioRxiv},
}
Figure